WO2000047582A1 - Derives de la triazolo-pyridazine, liants des recepteurs du gaba - Google Patents

Derives de la triazolo-pyridazine, liants des recepteurs du gaba Download PDF

Info

Publication number
WO2000047582A1
WO2000047582A1 PCT/GB2000/000308 GB0000308W WO0047582A1 WO 2000047582 A1 WO2000047582 A1 WO 2000047582A1 GB 0000308 W GB0000308 W GB 0000308W WO 0047582 A1 WO0047582 A1 WO 0047582A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
triazolo
triazol
compound
formula
Prior art date
Application number
PCT/GB2000/000308
Other languages
English (en)
Inventor
William Robert Carling
Andrew Mitchinson
Michael Geoffrey Neil Russell
Leslie Joseph Street
Original Assignee
Merck Sharp & Dohme Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Limited filed Critical Merck Sharp & Dohme Limited
Priority to EP00901765A priority Critical patent/EP1150983A1/fr
Priority to AU23065/00A priority patent/AU2306500A/en
Priority to CA002362400A priority patent/CA2362400A1/fr
Priority to JP2000598502A priority patent/JP2002536449A/ja
Publication of WO2000047582A1 publication Critical patent/WO2000047582A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

L'invention porte sur une classe de dérivés substitués de la 1,2,4-triazolo[4,3-b]pyridazine présentant un cycle phényle en position 3, et un fragment triazolyl-méthoxy à substitution C en position 6. Ces dérivés sont des liants sélectifs des récepteurs du GABAA présentant en particulier une forte affinité pour des sous-unités α2 et/ou α3, et s'avérant de ce fait intéressants pour le traitement et/ou la prévention de troubles du SNC dont l'anxiété et les convulsions.
PCT/GB2000/000308 1999-02-11 2000-02-02 Derives de la triazolo-pyridazine, liants des recepteurs du gaba WO2000047582A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00901765A EP1150983A1 (fr) 1999-02-11 2000-02-02 Derives de la triazolo-pyridazine, liants des recepteurs du gaba
AU23065/00A AU2306500A (en) 1999-02-11 2000-02-02 Triazolo-pyridazine derivatives as ligands for gaba receptors
CA002362400A CA2362400A1 (fr) 1999-02-11 2000-02-02 Derives de la triazolo-pyridazine, liants des recepteurs du gaba
JP2000598502A JP2002536449A (ja) 1999-02-11 2000-02-02 Ｇａｂａレセプターに対するリガンドとしてのトリアゾロ−ピリダジン誘導体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9903119.7A GB9903119D0 (en) 1999-02-11 1999-02-11 Therapeutic agents
GB9903119.7 1999-02-11

Publications (1)

Publication Number Publication Date
WO2000047582A1 true WO2000047582A1 (fr) 2000-08-17

Family

ID=10847573

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/000308 WO2000047582A1 (fr) 1999-02-11 2000-02-02 Derives de la triazolo-pyridazine, liants des recepteurs du gaba

Country Status (6)

Country Link
EP (1) EP1150983A1 (fr)
JP (1) JP2002536449A (fr)
AU (1) AU2306500A (fr)
CA (1) CA2362400A1 (fr)
GB (1) GB9903119D0 (fr)
WO (1) WO2000047582A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005039569A1 (fr) * 2003-10-18 2005-05-06 Bayer Healthcare Ag Derives de 2-(phenylmethyl)thio-4-phenyl-4h-1,2,4-triazole substitues en 5 et composes associes utilises en tant que gaba-agonistes dans le traitement de l'incontinence urinaire et des maladies associees
US6958334B2 (en) 2001-04-10 2005-10-25 Merck & Co., Inc. Inhibitors of Akt activity
US6960584B2 (en) 2001-04-10 2005-11-01 Merck & Co., Inc. Inhibitors of Akt activity
WO2005116014A1 (fr) 2004-05-12 2005-12-08 Pfizer Products Inc. Derives de proline et leur utilisation en tant qu'inhibiteurs de la dipeptidyl-peptidase iv
US7015224B2 (en) * 2001-09-20 2006-03-21 Merck Sharp & Dohme Ltd. 7-Tert-butyl-3-(2-fluorophenyl)-6-(2H-(1,2,4)triazol-3-ylmethoxy)-(1,2,4)triazolo (4,3b) pyridazine for the treatment of anxiety and convulsions
US7098208B2 (en) 2001-04-10 2006-08-29 Merck & Co., Inc. Inhibitors of Akt activity
WO2009061879A1 (fr) 2007-11-09 2009-05-14 Smithkline Beecham Corporation Inhibiteurs de la peptide déformylase
WO2017129801A1 (fr) * 2016-01-27 2017-08-03 Universität Zürich Utilisation de modulateurs des récepteurs gabaa pour le traitement des démangeaisons

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998004559A2 (fr) * 1996-07-25 1998-02-05 Merck Sharp & Dohme Limited Derives de triazolo-pyridazine substitues servant de ligands pour recepteurs de gaba

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998004559A2 (fr) * 1996-07-25 1998-02-05 Merck Sharp & Dohme Limited Derives de triazolo-pyridazine substitues servant de ligands pour recepteurs de gaba

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6958334B2 (en) 2001-04-10 2005-10-25 Merck & Co., Inc. Inhibitors of Akt activity
US6960584B2 (en) 2001-04-10 2005-11-01 Merck & Co., Inc. Inhibitors of Akt activity
US7098208B2 (en) 2001-04-10 2006-08-29 Merck & Co., Inc. Inhibitors of Akt activity
US7015224B2 (en) * 2001-09-20 2006-03-21 Merck Sharp & Dohme Ltd. 7-Tert-butyl-3-(2-fluorophenyl)-6-(2H-(1,2,4)triazol-3-ylmethoxy)-(1,2,4)triazolo (4,3b) pyridazine for the treatment of anxiety and convulsions
WO2005039569A1 (fr) * 2003-10-18 2005-05-06 Bayer Healthcare Ag Derives de 2-(phenylmethyl)thio-4-phenyl-4h-1,2,4-triazole substitues en 5 et composes associes utilises en tant que gaba-agonistes dans le traitement de l'incontinence urinaire et des maladies associees
WO2005116014A1 (fr) 2004-05-12 2005-12-08 Pfizer Products Inc. Derives de proline et leur utilisation en tant qu'inhibiteurs de la dipeptidyl-peptidase iv
EP2116541A1 (fr) 2004-05-12 2009-11-11 Pfizer Products Incorporated Dérivés de proline et leur utilisation en tant qu'inhibiteurs de la dipeptidyl-peptidase IV
WO2009061879A1 (fr) 2007-11-09 2009-05-14 Smithkline Beecham Corporation Inhibiteurs de la peptide déformylase
WO2017129801A1 (fr) * 2016-01-27 2017-08-03 Universität Zürich Utilisation de modulateurs des récepteurs gabaa pour le traitement des démangeaisons
US10786513B2 (en) 2016-01-27 2020-09-29 Universitat Zurich Use of GABAA receptor modulators for treatment of itch
US11529359B2 (en) 2016-01-27 2022-12-20 Universitat Zurich Use of GABAA receptor modulators for treatment of itch
AU2017213154B2 (en) * 2016-01-27 2023-02-02 Universität Zürich Use of GABAA receptor modulators for treatment of itch

Also Published As

Publication number Publication date
JP2002536449A (ja) 2002-10-29
AU2306500A (en) 2000-08-29
CA2362400A1 (fr) 2000-08-17
EP1150983A1 (fr) 2001-11-07
GB9903119D0 (en) 1999-04-07

Similar Documents

Publication Publication Date Title
EP1149102B1 (fr) Derives de triazolo-pyridazine tenant lieu de ligands pour recepteurs gaba
AU748737B2 (en) Triazolo-pyridazine derivatives as ligands for GABA receptors
US6303605B1 (en) Triazolo-pyridazine derivatives as ligands for GABA receptors
EP1090004B1 (fr) Derive de triazolo-pyridazine substitue et compositions pharmaceutiques fabriquees a partir de ce derive
US6337331B1 (en) Triazolo-pyrimidine as ligands for GABA receptors
US6303597B1 (en) Triazolo-pyridazine derivatives as ligands for GABA receptors
US6319924B1 (en) Triazolo-pyridazine derivatives as ligands for GABA receptors
EP1212324A1 (fr) Derives d'imidazo-triazine utiles comme ligands de recepteurs gaba
US6291460B1 (en) Triazolo-pyridazine derivatives as ligands for GABA receptors
WO2000047582A1 (fr) Derives de la triazolo-pyridazine, liants des recepteurs du gaba
US6699859B1 (en) Triazolo-pyridazine derivatives as ligands for GABA receptors
EP1430055A1 (fr) 7-tert-butyl-3-(2-fluorophenyl)-6-(2h-(1,2,4)triazol-3-ylmethoxy)-(1,2,4)triazolo(4,3-b) pyridazine pour traiter l'anxiete et les convulsions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2000901765

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09889999

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 23065/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2362400

Country of ref document: CA

Ref country code: CA

Ref document number: 2362400

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 598502

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000901765

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000901765

Country of ref document: EP